Bivalent TRK Degraders Using E3 Ligase Recruitment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diseases associated with tropomyosin receptor kinase (TRK) are limited in efficacy and specificity, particularly in targeting TRK proteins, mutants, and fusion proteins.
Innovation Solution
Development of bivalent compounds comprising a TRK ligand conjugated to a degradation tag, which can bind to TRK proteins and facilitate their degradation through ubiquitin ligases, utilizing specific E3 ligases like cereblon, VHL, MDM2, TRIM24, TRIM21, KEAP1, and TAP ligases, to enhance targeted protein degradation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional TRK inhibitors are used, then TRK activity is inhibited, but treatment efficacy and specificity are limited
Solution Approach 1:
The compound is divided into two functional segments: a TRK ligand portion that binds to TRK proteins with high specificity, and a degradation tag portion that recruits ubiquitin ligases. This segmentation allows each segment to perform its specialized function independently, achieving both high specificity through the ligand and high efficacy through complete protein degradation.
Solution Approach 2:
The patent merges the binding function (ligand) and the degradation function (degradation tag) into a single bivalent compound. This combination allows the compound to simultaneously bind to TRK proteins and trigger their degradation, overcoming the limitations of conventional inhibitors that only block activity without achieving complete removal of the target protein.
2Adaptability or versatility
If TRK proteins are targeted for degradation, then treatment specificity is improved, but mechanism complexity increases
Solution Approach 1:
The bivalent compound leverages the cell's own ubiquitin-proteasome system to degrade TRK proteins. The degradation tag portion of the compound recruits endogenous ubiquitin ligases (such as cereblon, VHL, MDM2, TRIM24, TRIM21, KEAP1, or TAP ligases), which then ubiquitinate and direct TRK proteins to the proteasome for degradation. This self-service approach achieves specific protein degradation without requiring complex external degradation machinery.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The bivalent compounds effectively degrade TRK proteins, providing a targeted and specific therapeutic approach for diseases involving TRK, enhancing treatment efficacy.
Implementation Method 1
a tropomyosin receptor kinase (TRK) ligand conjugated to a degradation tag
Implementation Method 2
the degradation tag binds to an ubiquitin ligase... to enhance targeted protein degradation
Data Source
AI summary
This disclosure relates to bivalent compounds (e.g., bi-functional small molecule compounds), compositions comprising one or more of the bivalent compounds, and to methods of use the bivalent compounds for the treatment of certain disease in a subject in need thereof. The disclosure also relates to methods for identifying such bivalent compounds.